JP7405834B2 - ピリジニルメチレンピペリジン誘導体及びその使用 - Google Patents
ピリジニルメチレンピペリジン誘導体及びその使用 Download PDFInfo
- Publication number
- JP7405834B2 JP7405834B2 JP2021509988A JP2021509988A JP7405834B2 JP 7405834 B2 JP7405834 B2 JP 7405834B2 JP 2021509988 A JP2021509988 A JP 2021509988A JP 2021509988 A JP2021509988 A JP 2021509988A JP 7405834 B2 JP7405834 B2 JP 7405834B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- title compound
- compound
- alkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810969837.5 | 2018-08-24 | ||
| CN201810969837 | 2018-08-24 | ||
| PCT/CN2019/101985 WO2020038435A1 (en) | 2018-08-24 | 2019-08-22 | Pyridinylmethylenepiperidine derivatives and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021536433A JP2021536433A (ja) | 2021-12-27 |
| JPWO2020038435A5 JPWO2020038435A5 (https=) | 2022-07-04 |
| JP2021536433A5 JP2021536433A5 (https=) | 2022-07-04 |
| JP7405834B2 true JP7405834B2 (ja) | 2023-12-26 |
Family
ID=68437065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021509988A Active JP7405834B2 (ja) | 2018-08-24 | 2019-08-22 | ピリジニルメチレンピペリジン誘導体及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11858910B2 (https=) |
| EP (1) | EP3841096A4 (https=) |
| JP (1) | JP7405834B2 (https=) |
| CN (1) | CN110437205B (https=) |
| AU (1) | AU2019323450B2 (https=) |
| CA (1) | CA3107145A1 (https=) |
| WO (1) | WO2020038435A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111187252B (zh) * | 2019-11-22 | 2023-06-09 | 广东东阳光药业有限公司 | 吡啶酰基氮杂螺庚烷衍生物及其用途 |
| CN111187251B (zh) * | 2019-11-22 | 2023-06-09 | 广东东阳光药业有限公司 | 吡啶酰基哌啶衍生物及其用途 |
| CN111943930B (zh) * | 2020-08-25 | 2022-11-01 | 南京三元阳普医药科技有限公司 | Lasmiditan的合成工艺 |
| CN114685443B (zh) * | 2020-12-29 | 2023-07-18 | 广东东阳光药业有限公司 | 吡啶烯基哌啶衍生物的盐及其用途 |
| CN114685440B (zh) * | 2020-12-29 | 2023-07-18 | 广东东阳光药业有限公司 | 吡啶烯基哌啶衍生物的盐及其用途 |
| US20240083870A1 (en) * | 2020-12-29 | 2024-03-14 | Sunshine Lake Pharma Co., Ltd. | Salts of pyridinylmethylenepiperidine derivatives and uses thereof |
| CN114685441B (zh) * | 2020-12-29 | 2023-07-18 | 广东东阳光药业有限公司 | 吡啶烯基哌啶衍生物的盐及其用途 |
| CN114685444B (zh) * | 2020-12-29 | 2023-07-18 | 广东东阳光药业有限公司 | 吡啶烯基哌啶衍生物的盐及其用途 |
| CN112939952A (zh) * | 2021-02-02 | 2021-06-11 | 深圳市第二人民医院(深圳市转化医学研究院) | 一种3-羟基查尔酮衍生物及其用途 |
| CN112898276A (zh) * | 2021-02-02 | 2021-06-04 | 深圳市第二人民医院(深圳市转化医学研究院) | 一种查尔酮衍生物及其用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005530722A (ja) | 2002-03-29 | 2005-10-13 | イーライ・リリー・アンド・カンパニー | ５−ｈｔ１ｆアゴニストとしてのピリジノイルピペリジン |
| JP2007505105A (ja) | 2003-09-12 | 2007-03-08 | イーライ リリー アンド カンパニー | ５−ｈｔ１ｆアゴニストとしての置換された２−カルボニルアミノ−６−ピペリジンアミノピリジンおよび置換された１−カルボニルアミノ−３−ピペリジンアミノベンゼン |
| JP2010506896A (ja) | 2006-10-18 | 2010-03-04 | ファイザー・プロダクツ・インク | ビアリールエーテル尿素化合物 |
| JP2011522845A (ja) | 2008-06-10 | 2011-08-04 | 江蘇国華投資有限公司 | アラルキルアルコールピペリジン誘導体及びその抗うつ病薬物としての使用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA979961B (en) | 1996-11-15 | 1999-05-05 | Lilly Co Eli | 5-HT1F agonists |
| US6133290A (en) | 1998-07-31 | 2000-10-17 | Eli Lilly And Company | 5-HT1F agonists |
| US6777428B1 (en) | 1999-02-10 | 2004-08-17 | Eli Lilly And Company | 5-HT1f agonist |
| MXPA05011223A (es) * | 2003-04-18 | 2006-01-26 | Lilly Co Eli | Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas 5-htif. |
| DE602004008338T2 (de) | 2003-12-17 | 2008-05-29 | Eli Lilly And Co., Indianapolis | Substituierte (4-aminocyclohexen-1-yl) phenyl and (4-aminocyclohexen-1-yl) pyridinyl verbindungen als 5-ht1f agonisten |
| TW201028421A (en) | 2009-01-15 | 2010-08-01 | Abbott Lab | Novel benzenesulfonamides as calcium channel blockers |
| GB201114448D0 (en) | 2011-08-22 | 2011-10-05 | Takeda Pharmaceutical | Compounds and their use |
| MX2016016488A (es) | 2014-08-27 | 2017-03-30 | Hoffmann La Roche | Derivados de azetidina sustituidos como ligandos de receptores asociados a aminas en trazas (taar). |
| GB201416513D0 (en) * | 2014-09-18 | 2014-11-05 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
-
2019
- 2019-08-22 WO PCT/CN2019/101985 patent/WO2020038435A1/en not_active Ceased
- 2019-08-22 CA CA3107145A patent/CA3107145A1/en active Pending
- 2019-08-22 US US17/263,177 patent/US11858910B2/en active Active
- 2019-08-22 AU AU2019323450A patent/AU2019323450B2/en active Active
- 2019-08-22 CN CN201910778613.0A patent/CN110437205B/zh active Active
- 2019-08-22 EP EP19851618.9A patent/EP3841096A4/en active Pending
- 2019-08-22 JP JP2021509988A patent/JP7405834B2/ja active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005530722A (ja) | 2002-03-29 | 2005-10-13 | イーライ・リリー・アンド・カンパニー | ５−ｈｔ１ｆアゴニストとしてのピリジノイルピペリジン |
| JP2007505105A (ja) | 2003-09-12 | 2007-03-08 | イーライ リリー アンド カンパニー | ５−ｈｔ１ｆアゴニストとしての置換された２−カルボニルアミノ−６−ピペリジンアミノピリジンおよび置換された１−カルボニルアミノ−３−ピペリジンアミノベンゼン |
| JP2010506896A (ja) | 2006-10-18 | 2010-03-04 | ファイザー・プロダクツ・インク | ビアリールエーテル尿素化合物 |
| JP2011522845A (ja) | 2008-06-10 | 2011-08-04 | 江蘇国華投資有限公司 | アラルキルアルコールピペリジン誘導体及びその抗うつ病薬物としての使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3841096A4 (en) | 2022-05-18 |
| CA3107145A1 (en) | 2020-02-27 |
| EP3841096A1 (en) | 2021-06-30 |
| WO2020038435A1 (en) | 2020-02-27 |
| US20210188803A1 (en) | 2021-06-24 |
| AU2019323450A1 (en) | 2021-02-11 |
| AU2019323450B2 (en) | 2025-04-10 |
| CN110437205B (zh) | 2022-07-08 |
| CN110437205A (zh) | 2019-11-12 |
| JP2021536433A (ja) | 2021-12-27 |
| US11858910B2 (en) | 2024-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7405834B2 (ja) | ピリジニルメチレンピペリジン誘導体及びその使用 | |
| JP7282082B2 (ja) | 置換ピリミジンピペラジン化合物及びその使用 | |
| CN111333648B (zh) | 8-取代的芳香环乙烯基黄嘌呤衍生物及其用途 | |
| CN111004214B (zh) | 吡啶酰基哌啶衍生物及其用途 | |
| CN110272425B (zh) | 吡啶酰基八氢吡咯并[3,4-c]吡咯衍生物及其用途 | |
| CN112300165B (zh) | 8-取代的苯乙烯基黄嘌呤衍生物及其用途 | |
| CN110981876B (zh) | 8-取代的苯乙烯基黄嘌呤衍生物及其用途 | |
| CN111187252B (zh) | 吡啶酰基氮杂螺庚烷衍生物及其用途 | |
| CN111187251B (zh) | 吡啶酰基哌啶衍生物及其用途 | |
| CN110845402B (zh) | 吡啶亚甲基哌嗪衍生物及其用途 | |
| CN110938068B (zh) | N-(吗啉-2-基甲基)酰胺衍生物及其用途 | |
| WO2021097781A1 (zh) | 吡啶亚甲基哌啶衍生物及其用途 | |
| CN111018856B (zh) | 8-取代的苯乙烯基黄嘌呤衍生物及其用途 | |
| CN111072676B (zh) | 含氮稠合三环衍生物及其用途 | |
| CN112010818B (zh) | 吗啉酰胺衍生物及其用途 | |
| CN109734712B (zh) | 芳基或杂芳基取代的吡咯烷酰胺衍生物及其用途 | |
| CN111072604B (zh) | α-氨基酰胺衍生物及其用途 | |
| CN110938064B (zh) | N-取代哌啶酰胺衍生物及其用途 | |
| CN111072675A (zh) | 含氮稠合三环衍生物及其用途 | |
| CN111072663B (zh) | 8-取代的苯乙烯基黄嘌呤衍生物及其用途 | |
| CN109761892B (zh) | 含氮杂环基团取代的酰胺衍生物及其用途 | |
| CN110950843B (zh) | 取代的苯酰胺衍生物及其用途 | |
| CN118063445A (zh) | 吡咯烷酰胺衍生物及其用途 | |
| CN118063444A (zh) | 氮杂环丁烷酰胺衍生物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220624 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220624 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230622 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230626 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230926 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231006 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231211 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231214 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7405834 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |